D. Boral Capital Reiterates “Buy” Rating for Imunon (NASDAQ:IMNN)

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $29.00 target price on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Imunon in a research note on Thursday, December 19th.

Imunon Stock Performance

Shares of IMNN opened at $0.87 on Wednesday. The firm has a market cap of $12.64 million, a P/E ratio of -0.46 and a beta of 2.03. Imunon has a 52 week low of $0.52 and a 52 week high of $3.65. The firm’s 50-day simple moving average is $0.89 and its 200 day simple moving average is $0.96.

Institutional Trading of Imunon

A hedge fund recently raised its stake in Imunon stock. Geode Capital Management LLC lifted its holdings in shares of Imunon, Inc. (NASDAQ:IMNN) by 10.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 139,505 shares of the company’s stock after purchasing an additional 13,570 shares during the quarter. Geode Capital Management LLC owned 0.96% of Imunon worth $133,000 as of its most recent SEC filing. Institutional investors own 4.47% of the company’s stock.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.